CJC 1295
(08)
Overview
CJC-1295 is a long-acting growth hormone–releasing hormone (GHRH) analog engineered with a drug-affinity complex to prolong half-life; it has been studied for raising GH/IGF-1 but is not FDA-approved for any indication, and long-term safety/effectiveness have not been established.
Category
GH Secretagogue Peptide
Challenge
Extend half-life via albumin-binding (DAC) without losing GHRH-receptor selectivity or bioactivity. Control conjugation chemistry and impurities (aggregation, immunogenic adducts), and design a lyophilized formulation/reconstitution medium that protects the peptide-DAC linkage (from oxidation/hydrolysis) while preserving physiologic GH pulsatility.
Impact